Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Clinical trial NCT00111696 · COMPLETED

Trial details

NCT number: NCT00111696
Sponsor: MedImmune LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Melanoma

Start date: 2005-05-01
Primary completion: 2007-08-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.